Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996 Jun;34(6):1022-9
Date
06/01/1996Pubmed ID
8647968DOI
10.1016/s0190-9622(96)90282-0Scopus ID
2-s2.0-0029982190 (requires institutional sign-in at Scopus site) 80 CitationsAbstract
BACKGROUND: Cutaneous T-cell lymphoma (CTCL) may respond to many therapies, but long-term disease-free survival is uncommon. Patients with advanced disease have a median survival of approximately 3 years.
OBJECTIVE: Our purpose was to combine known effective agents sequentially to determine whether we could achieve remission in more patients or for longer duration.
METHODS: Patients with mycosis fungoides (n = 23) or Sézary syndrome (n = 5) were treated with 4 months of recombinant interferon alfa together with isotretinoin, followed by total skin electron beam therapy alone (for stage I to II disease) or preceded by chemotherapy (for stage III to IV disease). Maintenance therapy consisted of interferon for 1 year and topical nitrogen mustard for 2 years.
RESULTS: Twenty-eight patients were treated. The overall response rate (complete and partial remissions) was 82%. Although the median duration of remission was 5 months in patients with stage III to IV disease, two patients remain in complete remission at 39 + and 46 + months. In patients with stage I to II disease the median duration of remission has not been reached at a median follow-up of 18 months. Five patients, all with stage III to IV disease, have died. Overall, the regimen was well tolerated with one treatment-related death from neutropenic sepsis.
CONCLUSION: Combined modality therapy may be effective for the treatment of CTCL with similar response rates to other current therapies.
Author List
Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Administration, CutaneousAdult
Aged
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Cause of Death
Combined Modality Therapy
Disease-Free Survival
Female
Follow-Up Studies
Humans
Interferon Type I
Isotretinoin
Keratolytic Agents
Male
Mechlorethamine
Middle Aged
Mycosis Fungoides
Neoplasm Staging
Radiotherapy Dosage
Radiotherapy, High-Energy
Recombinant Proteins
Remission Induction
Sezary Syndrome
Skin Neoplasms
Survival Rate
